A 12-month programme will allow Manus to utilise the Association of British HealthTech Industries (ABHI) expertise and connections.
Manus Neurodynamica Limited (Manus) develops and markets products and technologies for neuromotor assessment globally. It announced that it has joined the Association of British HealthTech Industries (ABHI) 2022 US accelerator programme. This will allow Manus to use ABHI’s expertise and connections within the US to strengthen strategy and de-risk the market.
The ABHI US Accelerator is now in its fifth year and is conducted in partnership with the Dell Medical School in Austin Texas. It supports UK medical device, diagnostic and digital health companies that are looking to enter the US healthcare space. The year-long programme provides such companies with an opportunity to define and strengthen their US strategy, de-risk market entry and develop their business. Companies gain access to any advice, expertise and connections within the country offered by ABHI.
The 2022 ABHI US Accelerator programme will run from January 2022 until December 2022.
Manus and ABHI
Manus joins the ABHI US Accelerator programme at a crucial time in the company’s US regulatory pathway.
In December 2021, Manus was granted Breakthrough Designation by the US Food and Drug Administration (FDA) for its Neuromotor Pen™ device. This was a significant step toward the technology gaining approval in the US. The Breakthrough designation was granted for its proposed indication of supporting healthcare providers in differentiating between Parkinsonian and non-Parkinsonian tremours in adult patients who are suspected to have the condition.
Manus is currently working on a study protocol with the FDA ahead of a US-based clinical trial which would demonstrate a high specificity and sensitivity in differential diagnostic decision making as achieved in European trials.
Over the next 12 months, ABHI will work alongside Manus and 39 other companies that have been successful in gaining space on the 2022 programme. ABHI will provide support in identifying and filling need gaps and setting individual goals to support their growth. The companies will also be boosted by access to an expansive network of in-market experts.
ABHI Expertise
Paul Benton, managing director, ABHI International, said: “We are delighted that our programme continues to attract such high calibre applicants. The ABHI US Accelerator is a fantastic platform for UK HealthTech innovators looking to access the US healthcare landscape.
In helping companies de-risk US market entry, it also acts as a catalyst for growth, offering access to senior physicians, c-suite level health system executives, payers and a broad network of US healthcare contacts. We look forward to supporting each company in their goal to grow and develop within one of the world’s largest HealthTech markets.”
Dr Rutger Zietsma, CEO of Manus, commented: “I am pleased that we have been accepted on the ABHI US Accelerator programme for 2022, where we are a part of a cohort of highly innovative companies with the potential to make a significant impact on US healthcare.
Combined with our recently granted Breakthrough Designation, this has been a greatly encouraging start to accessing the US markets. We look forward to working with ABHI and its key contacts and expertise within the US to help facilitate our goal of achieving regulatory approval for the differential diagnosis of Parkinson’s Disease, and help improve the lives of this large, underserved patient population.”
